Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO TAT 2023 | Characterizing and targeting class II/III BRAF alterations

Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York, NY, describes the classes of BRAF mutations and current treatment options for BRAF-mutant tumors. Class I and II mutations are V600E and non-V600E mutations with kinase activity respectively, whereas class III mutations have low or no kinase activity. Current BRAF inhibitors such as vemurafenib, dabrafenib and encorafenib are not efficacious in class II and III mutations. Targeting upstream with antibodies such as cetuximab are seen as promising strategies. This interview took place at the ESMO Targeted Anticancer Therapies (TAT) Congress 2023 in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.